Skip to main content

Table 2 Comparison of bone structure and biomechanical properties in no-DMARD-, methotrexate-, and bDMARD-treated PsA patients

From: Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients

  No DMARDs (N = 79) Methotrexate (N = 34) bDMARDs (N = 52) p value
a/b
Finite element analysis
 Stiffness (kN/mm), (mean ± SD) 45.2 ± 13.7 46.7 ± 14.2 52.1 ± 15.0 b −/0.012
 Failure load (N), (mean ± SD) 2154 ± 621 2242 ± 645 2473 ± 704 b −/0.012
Bone parameters
 Volumetric bone mineral density
  Dtotal mg HA/cm3, (mean ± SD) 290 ± 54 299 ± 63 320 ± 44 b −/0.001
  Dtrab, mg HA/cm3, (mean ± SD) 156 ± 39 166 ± 40 174 ± 36 b −/0.005
  Dmeta, mg HA/cm3, (mean ± SD) 214 ± 38 222 ± 39 236 ± 35 b −/0.001
  Dinn, mg HA/cm3, (mean ± SD) 116 ± 41 127 ± 43 132 ± 40 b −/0.026
  Dcomp, mg HA/cm3, (mean ± SD) 817 ± 57 817 ± 72 831 ± 43 −/−
  Meta/Inn, %, (mean ± SD) 1.9 ± 0.5 1.9 ± 0.8 2.0 ± 0.8 −/−
 Bone microstructure
  BV/TV, %, (mean ± SD) 0.13 ± 0.03 0.14 ± 0.03 0.15 ± 0.03 b −/0.005
  Tb.N, 1/mm, (mean ± SD) 1.99 ± 0.35 2.05 ± 0.36 2.12 ± 0.32 b −/0.022
  TbTh, mm, (mean ± SD) 0.065 ± 0.010 0.067 ± 0.011 0.069 ± 0.010 b −/0.030
  Tb.Sp, mm, (mean ± SD) 0.47 ± 0.18 0.44 ± 0.10 0.42 ± 0.11 b −/0.010
  Tb.1/N.SD, mm, (mean ± SD) 0.21 ± 0.16 0.19 ± 0.08 0.19 ± 0.13 b −/0.017
  Ct.Th, mm, (mean ± SD) 0.71 ± 0.16 0.73 ± 0.18 0.80 ± 0.15 b −/0.001
 Bone area
  Cross-sectional area (mean ± SD) 321 ± 76 335 ± 88 325 ± 80 −/−
  1. Bonferroni-Holm adjustment: critical p values indicating significant results (bold p values) for all investigated parameters were as follows: p1 = 0.0167, p2 = 0.025, p3 = 0.05
  2. bDMARDs biologic disease-modifying anti-rheumatic drugs, Dtotal total vBMD, Dtrab trabecular vBMD, Dcomp compact vBMD, Dmeta meta trabecular vBMD, Dinn inner trabecular vBMD, meta/inn ratio of meta-to-inner density, BV/TV trabecular bone volume fraction, Tb.N number of trabeculae, Tb.Th trabecular thickness, Tb.Sp trabecular separation, Tb.1/N.SD inhomogeneity of network, Ct.Th cortical thickness, a/b: a no DMARDs vs. methotrexate, b no DMARDs vs. bDMARD